TABLE 3.
Biosimilar candidates as Part B reimbursed biologicals (biosimilars in bold) with only one drug (*) with $1B+ expenditure
| *Abatacept | Abobotulinumtoxina | Ado‐Trastuzumab Emtansine | *Aflibercept | Agalsidase Beta |
|---|---|---|---|---|
| Albumin Human | Alemtuzumab | Alglucosidase Alfa | Alpha‐1‐Proteinase Inhibitor | Alteplase |
| Anti‐Inhibitor Coagulant Comp. | Anti‐Thymocyte Globulin, rabbit | Antihem. FVIII, several types | Antihemophilic Factor/VWF | Antithrombin III (Hum Plas) |
| Antivenin, crotalidae Fab(Ovin) | Asparaginase (Erwinia Chrysan) | Atezolizumab | Avelumab | Basiliximab |
| Belatacept | Belimumab | Bendamustine HCL | Benralizumab | Bevacizumab |
| Bezlotoxumab | Blinatumomab | Bortezomib | Brentuximab Vedotin | Brolucizumab‐Dbll |
| Burosumab‐Twza | C1 Esterase Inhibitor, Recomb | Canakinumab/PF | Carfilzomib | Cemiplimab‐Rwlc |
| Certolizumab Pegol | Cetuximab | Chorionic Gonadotropin, Human | Coagulation Factor VIIA, recomb | Coagulation Factor X |
| Crizanlizumab‐Tmca | Daratumumab | Darbepoetin Alfa In Polysorbat | *Denosumab | Digoxin Immune Fab |
| Dornase Alfa | Durvalumab | Eculizumab | Elotuzumab | Emicizumab‐Kxwh |
| Enfortumab Vedotin‐Ejfv | Epoetin Alfa | Factors IX several types | Factor XIII several types | Fam‐Trastuzumab Deruxtecn‐Nxki |
| Filgrastim | Gemtuzumab Ozogamicin | Glucagon, human Recombinant | Golimumab | Ibalizumab‐Uiyk |
| Idursulfase | Imiglucerase | Imm Glob G (Igg)/Sorb/Iga 0–50 | Incobotulinumtoxina | Infliximab |
| Inotuzumab Ozogamicin | Insulin Aspart | Insulin Lispro | Interferon Alfa‐2b, recomb. | Interferon Beta‐1a |
| Ipilimumab | Isatuximab‐Irfc | Mepolizumab | Methoxy Peg‐Epoetin Beta | Mogamulizumab‐Kpkc |
| Moxetumomab Pasudotox‐Tdfk | Natalizumab | Necitumumab | *Nivolumab | Obinutuzumab |
| Ocrelizumab | Ocriplasmin/PF | Ofatumumab | Olaratumab | Omalizumab |
| Onabotulinumtoxina | Panitumumab | Pegaspargase | Pegfilgrastim | Pegloticase |
| *Pembrolizumab | Pertuzumab | Polatuzumab Vedotin‐Piiq | Ramucirumab | *Ranibizumab |
| Ravulizumab‐Cwvz | Reslizumab | Rho(D) Immune Globulin | Rimabotulinumtoxinb | *Rituximab |
| Rituximab/Hyaluronidase, human | Romosozumab‐Aqqg | Sargramostim | Siltuximab | Tagraxofusp‐Erzs |
| Taliglucerase Alfa | Teprotumumab‐Trbw | Thyrotropin Alfa | Tildrakizumab‐Asmn | Tocilizumab |
| Trastuzumab | Trastuzumab‐Hyaluronidase‐Oysk | Treprostinil | Ustekinumab | Vedolizumab |
| Velaglucerase Alfa | Von Willebrand Factor | Ziv‐Aflibercept |
Note: Adalimumab is classified under Part D.